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Abstract
The parametric responsemap (PRM) was evaluated as an early surrogate biomarker for monitoring treatment-induced
tissue alterations in patients with head and neck squamous cell carcinoma (HNSCC). Diffusion-weighted magnetic
resonance imaging (DW-MRI) was performed on 15 patients with HNSCC at baseline and 3 weeks after treatment
initiation of a nonsurgical organ preservation therapy (NSOPT) using concurrent radiation and chemotherapy. PRM
was applied on serial apparent diffusion coefficient (ADC) maps that were spatially aligned using a deformable image
registration algorithm to measure the tumor volume exhibiting significant changes in ADC (PRMADC). Pretherapy and
midtherapy ADC maps, quantified from the DWIs, were analyzed by monitoring the percent change in whole-tumor
mean ADC and the PRM metric. The prognostic values of percentage change in tumor volume and mean ADC and
PRMADC as a treatment response biomarker were assessed by correlating with tumor control at 6 months. Pixel-wise
differences as part of PRMADC analysis revealed regions where water mobility increased. Analysis of the tumor ADC
histograms also showed increases inmean ADC as early as 3weeks into therapy in patientswith a favorable outcome.
Nevertheless, the percentage change in mean ADCwas found to not correlate with tumor control at 6 months. In con-
trast, significant differences in PRMADC and percentage change in tumor volumewere observed between patientswith
pathologically different outcomes. Observations from this study have found that diffusion MRI, when assessed by
PRMADC, has the potential to provide both prognostic and spatial information during NSOPT of head and neck cancer.
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Introduction
Head and neck squamous cell carcinoma (HNSCC) accounts for 2.5%
of all patients whose conditions were newly diagnosed with cancer [1].
Patients whose conditions were diagnosed with locoregional disease have
a 5-year relative survival rate of less than 60% [1]. In addition to the poor
prognosis, the quality of life of the patient may be affected from over-
exposure of sensitive areas to radiotherapy. To date, nonsurgical organ
preservation therapy (NSOPT) is the standard of care resulting in pres-
ervation of the functionality (e.g., swallowing and speech) in the patient
while maintaining the same survival rate.
Medical imaging has proven beneficial in diagnosing the conditions
of patients with HNSCC [2–8], but little improvement has been made
on using these image modalities for monitoring early treatment re-
sponse. Diffusion magnetic resonance imaging (MRI) has been used
for identifying malignancy [3, 5, 9–12] as well as determining late re-
currences [13]. Recent work by Kim et al. [14] has shown the utility of
diffusion MRI as a surrogate biomarker for early treatment response in
HNSCC patients. In that study, changes in whole-tumormean apparent
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diffusion coefficient (ADC), a metric of random thermal motion, of
water from pretherapy to 1 week into chemoradiotherapy was shown
to correlate with clinical or pathologic assessment of disease. The rise
in ADC within complete responders (CRs) after therapy suggested a loss
of cell density, which has been observed in previous studies [15,16].
Recently, a voxel-wise approach to evaluate ADC changes was devel-
oped [17] and validated [18–20] as an early biomarker for quantify-
ing the spatially heterogeneous response of tumors to therapy. This
approach uses registered baseline and early-treatment ADCmaps to cal-
culate regional response that may be more sensitive to cellular changes
than measurements of the mean change in ADC. This voxel-wise analy-
sis in its most general form is termed the parametric response map
(PRM [21]; previously referred to as the functional diffusion map
[17]). In a cohort of patients with malignant brain tumors, early diffu-
sion analysis 3 weeks into therapy using PRMADC was prognostic for
later radiographic response [18], time to progression, and overall sur-
vival [19], whereas percentage change in mean ADC had failed to dem-
onstrate any predictive value of survival.
We report on the use of diffusion-weighted magnetic resonance
imaging (DW-MRI) and PRM analysis in 15 patients with HNSCC
treated with NSOPT. The mean ADC at 3 weeks after treatment initia-
tion was found to significantly increase in CRs unlike in partial respond-
ers (PRs) where negligible changes were observed. Nevertheless, the
percentage change in mean ADC was not found to be significant be-
tween PRs and CRs. In contrast, regions of significantly increasing
ADC, as assessed by PRM, were found to be significantly larger in
CRs than in PRs.
Materials and Methods
Patients
A total of 23 patients were enrolled on an institutional review board–
approved prospective trial. Eight patients cannot be evaluated because
of claustrophobia [2], metal implants [2], withdrew from study [3], and
technical difficulties in diffusion scan [1], leaving 15 patients (Table 1).
All patients had AJCC stage III/IV disease and, based on the recom-
mendation of a multidisciplinary head and neck tumor board, were to
receive primary treatment with concurrent chemotherapy and radiation.
Radiation therapy (RT) was delivered according to standard institu-
tional practice with three-dimensional conformal treatment or intensity-
modulated RTwith 70Gy delivered to the gross tumor volumes (nodal or
primary), 60 to 63 Gy to high-risk nodal volumes, and 50 to 59.4 Gy
delivered to low-risk nodal volumes. At the time of analysis, 2 patients
had died of progressive disease, whereas 13 were still alive.
Informed consent was obtained from all patients who were serially
imaged approximately 1 week before and approximately 3 weeks after
the start of treatment. Tumor response was determined by computed
tomography and/or MRI 2 weeks from the end of RT. In addition, a
total of six patients had some form of surgical intervention (neck
dissection or biopsy) after the completion of RT because of clinical
practice or concern for residual mass. Scoring all patients as clinically
progressive was done so after tissue confirmation of progression and/or
metastatic disease. Patients were stratified by clinical outcome 6 months
from the start of treatment into those with (PR, n = 3) or without (CR,
n = 12) progression.
Magnetic Resonance Imaging
All MRI scans were acquired on a 3-T Philips Achieva MRI system
(Best, the Netherlands) using an eight-channel head and neck phased-
array coil. A head and neck protocol which included a fat-suppressed turbo
spin-echo T2-weighted sequence (field of view [FOV], 240 × 192 mm;
matrix, 320 × 256; slice thickness, 4 mm; slices, 30; repetition time/echo
time [TR/TE], 5000:120 milliseconds; echo train length [ETL], 15),
a non–contrast-enhanced and a gadolinium–diethylenetriamine penta-
acetic acid (Gd-DTPA; Bayer HealthCare Pharmaceuticals, Wayne,
NJ)–enhanced three-dimensional fast field echo T1-weighted sequence
(FOV, 240 × 240 mm; matrix, 240 × 240; slice thickness, 1 mm; slices,
160; TR/TE/inversion time [TI], 9.9:4.6:1040 milliseconds; turbo
factor of 200 echoes), and a DW, single-shot, spin-echo, echo-planar
imaging (EPI) series (FOV, 270 × 270 mm; matrix, 205 × 205; slice
thickness, 4 mm; slices, 24; TR/TE, 2789:59 milliseconds; b factor,
0 and 800 sec/mm2) with diffusion sensitization along three orthogonal
directions. All images were acquired with a SENSitivity Encoding
(SENSE) acquisition scheme [22]. The SENSE factor for all images
was 2, except the diffusion scans that had a SENSE factor of 3.9.
The total duration of this acquisition protocol (including patient setup)
was approximately 35 to 60 minutes, with the DW images (DWIs)
contributing approximately 2 minutes of scan time.
The product of the three orthogonal DWIs exhibits strong sensitivity
to diffusion but without sensitivity to the structural directionality of the
tissues. This isotropic feature was crucial for following serial changes in
Table 1. Clinical Characteristics.
Number Location of Primary Stage Chemotherapy Further Surgery Disease Status at 6 Months
1 Right tonsil IVB (T4 N2b) Cis-5FU Yes NED
2 Left base of tongue IVB (T3 N3) Carbo-Taxol Yes NED
3 Left soft palate IVB (T2 N3) Carbo-Taxol No Local and regional progression
4 Left tonsil III (T1 N2a) Carbo-Taxol No NED
5 Left tonsil IVB (T4 N2c) Cis-5FU No NED
6 Right tonsil IVB (T2 N3) Cisplatin Yes Regional progression
7 Left tonsil IVB (T4 N2) Carbo-Taxol Yes Local and regional progression
8 Left base of tongue IVB (T2 N3) Carbo-Taxol No NED
9 Left base of tongue III (T3 N0) Carbo-Taxol No NED
10 Unknown primary III (TX N2a) Cisplatin No NED
11 Left nasopharynx III (T2 N2) Cisplatin No NED
12 Left pyriform sinus III (T1 N2b) Carbo-Taxol Yes NED
13 Left tonsil III (T2 N2b) Carbo-Taxol Yes NED
14 Left tonsil III (T2 N2b) Carbo-Taxol No NED*
15 Left tonsil III (T2 N2b) Carbo-Taxol No NED
*Patient with late local and metastatic progression.
NED indicates no evidence of disease.
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water diffusion without confounding effects due to tissue orientation.
ADC maps were calculated from the DWIs as follows:
ADC = ln
Sb0
Sb1
 
= b1 − b0ð Þ ð1Þ
where S is the DWI at b values of b0 = 0 and b1 = 800 sec/mm
2.
Subsequent to image registration, contours were manually drawn
over tumors as delineated on T2-weighted, T1-weighted or contrast-
enhanced images by two independent radiologists or radiation oncologist
(S.K.M., A.E., or D.A.H., respectively). From the volume-of-interest
(VOI) tumor volume and mean ADC were assessed before and 3 weeks
after treatment initiation.
Image Registration
Subsequent to contouring the tumors, a geometric warping inter-
polant, that is, thin-plate spline, algorithm was used to map (warp)
the tumor volumes from interval examinations onto the tumor volumes
from pretherapy b0 DWIs (reference data set). Registration was based
on the optimization of mutual information between two image data
sets and implemented through the use of control points. User input
was required for selecting the initial three control points, with addi-
tional points performed automatically, in the midtherapy data set that
correspond to locations within the VOI of the reference data set. Sus-
ceptibility artifacts and patient motion during scanning resulted in
misalignment of DWIs to VOIs contoured on anatomic images. Re-
alignment was performed by first warping the b0 DWIs to the T1-
weighted contrast-enhanced data sets at the pretherapy time point.
Subsequent registration of interval examinations were warped to the
VOI of the pretherapy b0 DWIs. As a result of the deformable registra-
tion, all serial tumor volumes, as determined by the contours, encom-
passed the same three-dimensional space as the pretherapy tumor
volume. Therefore, only the pretherapy contour was required for per-
forming PRM. All registration was performed using MIAMI-Fuse,
which is an in-house image registration software developed by our
group [23].
Parametric Response Map
The PRM of ADC (PRMADC) was determined by first calculating
the difference between the ADC values (ΔADC =midtreatment ADC −
pretreatment ADC) for each voxel within the tumor pretreatment and
at 3 weeks after treatment initiation. Voxels yielding ΔADC greater
than a predetermined threshold set to 25 ADC units (×10−5 mm2/sec;
details described below) were designated as significantly increased and
were encoded in red (i.e., ΔADC > 25 × 10−5 mm2/sec). Blue voxels
represent volumes whose ADC values significantly decreased by more
than 25 × 10−5 mm2/sec (i.e., ΔADC < −25 × 10−5 mm2/sec) and the
green voxels within the tumor represent unchanged ADC values (i.e.,
absolute value of ΔADC was ≤25 × 10−5 mm2/sec). The volume frac-
tions within the tumor as determined by PRMADC were denoted by
PRMADC+ (increased ADC), PRMADC− (decreased ADC), and
PRMADC0 (unchanged ADC). PRM thresholds of significant change
were empirically assessed over a range of ΔADCs (0-70), and the
optimal threshold was determined from a receiver operating character-
istic (ROC) curve analysis of PRMADC+ and PRMADC− for predicting
tumor control at 6 months from the end of treatment. PRMADC+
with a threshold of ±25 ADC units provided the best correlation with
tumor control.
Statistical Analysis
A paired 2-tailed Student’s t test was used for comparison of baseline
tumor volume and mean ADC with 3-week midtreatment values. In
addition, differences in tumor volume and mean ADC, at individual
time points, were assessed between patients with clinically progressive
and nonprogressive disease and between primary and lymph node tumor
lesions by an unpaired 2-tailed Student’s t test. Group comparisons were
also performed for percentage change in tumor volume and mean ADC
and PRMADC. The correlation of the representative imaging parameters
with tumor control at 6 months after treatment initiation was assessed
by an ROC curve analysis. All statistical computations were performed
with a statistical software package (SPSS; SPSS, Inc, Chicago, IL), and
results were declared statistically significant at P < .05.
Results
Clinical Data
A total of 15 patients were evaluated, and at the time of analysis, 2 pa-
tients had died of progressive disease while 13 were still alive. Eleven of
these had no evidence of recurrence and two had recurrence (one with
nodal recurrence and one with both local and metastatic progressions;
Table 1). Because of N2 or N3 lymph nodes, a total of three patients
(Table 1: nos. 1, 2, and 6) underwent planned surgical dissection of re-
gional lymph nodes after the completion of RT; therefore, these nodal
volumes could not be included for later radiographic evaluation because
they were surgically resected before the 12-week time point.
Representative Patients
Figure 1 displays unregistered pretreatment (top row) and 3 weeks after
treatment initiation (bottom row) MR images along with corresponding
ADC histograms from the whole-tumor volume for a patient with a
HNSCC of the left base of the tongue. Enlarged right cervical lymph
nodes, denoted within the yellow dashed region, are readily evident as
hyperintense lesions on T2-weighted and contrast-enhanced images (Fig-
ure 1, A and C ) and as hypointense lesions on T1-weighted images
(Figure 1B). The pathologically enlarged lymph nodes are also apparent
on the ADC maps (Figure 1D) with values shown to be inversely cor-
related with cellular density [24] greater than the adjacent muscle. The
corresponding pretreatment diffusion histogram reflects a broad ADC
distribution with some areas exhibiting a very low ADC consistent with
high cellularity with ameanADCof 120 × 10−5mm2/sec. At 3weeks after
treatment initiation, the nodal tumor volume had increased by 2.6%,
whereas a 27.5% rise in mean tumor ADC to 153 × 10−5 mm2/sec was
observed. Given the large nodal disease and minimal volumetric response,
this patient underwent a clinically necessitated cervical lymph node dis-
section that revealed no evidence of residual disease (CR) and was alive
and free of disease 35 months from the completion of treatment.
Figure 2 displays unregistered before (top row) and 3 weeks after treat-
ment initiation images (bottom row) along with corresponding ADC
histograms from the whole-tumor volume for a patient treated for
HNSCC of the right tonsil. Enlarged lymph nodes were found to be
hypointense onT1-weighted images and hyperintense onT2-weighted im-
ages and were determined to enhance in the presence of a contrast agent
on T1-weighted images. A mean tumor ADC of 117 × 10
−5 mm2/sec
was measured before treatment, which increased by 17.9% to 138 ×
10−5 mm2/sec at 3 weeks after treatment initiation. At the 3-week time
point, nodal volumes were found to be 11% smaller. Subsequently,
this patient underwent a salvage neck dissection, and despite a greater
shrinkage in tumor, there were residual viable tumor cells identified in
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the nodal dissection. The clinical outcome of this patient was PR, and
the patient was free of disease at 16 months after salvage surgery.
Whole-Tumor Analysis of Volume and ADC
A total of 26 lesions, 12 primary tumors and 14 lymphnode volumes,
were analyzed to determine whether differences in whole-tumor mean
ADC values were evident between primary and lymph node tumors
before and 3 weeks after treatment induction. No significant difference
in mean ADC was observed between primary tumor and the nodal
masses at baseline or 3 weeks after treatment initiation (Table 2). At
the 3-week interval, mean ADC values of lymph nodes significantly
increased from baseline values (P < .0001) with significant observable
tumor shrinkage found in both primary (P = .005) and lymph node
(P < .0001) tumors. Although not significant, primary lesions revealed
a trend of increased mean ADC after treatment (P = .06). Because
primary and lymph node tumors’ responses to treatment were similar,
primary lesions and nodal masses were pooled for correlation of ADC
changes with patient outcome information.
Between clinical groups, no significant tumor volumetric differences
were observed at the 3-week posttreatment induction time interval. In
Figure 2. Unregistered before (top row) and 3 weeks after treatment initiation (bottom row): (A) T2-weighted, (B) T1-weighted, (C) contrast-
enhanced T1-weighted images, and (D) ADC maps with corresponding (E) ADC histograms from the whole tumor from a patient treated
for HNSCC of the right tonsil. The tumor is encompassed within the yellow contour. The clinical outcome of this patient was a PR.
Figure 1. Unregistered before (top row) and 3 weeks after treatment initiation (bottom row): (A) T2-weighted, (B) T1-weighted, (C) contrast-
enhanced T1-weighted images, and (D) ADC maps with corresponding (E) ADC histograms from the whole tumor of a patient treated
for HNSCC of the left base of the tongue. The tumor is outlined by the yellow contour line. This patient was subsequently determined to
be a CR to therapy.
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contrast, tumor volumes in both patient groups were found to signifi-
cantly decrease from baseline values at 3 weeks after treatment initia-
tion. However, before and after treatment, no significant differences
were observed in tumor mean ADC when stratified by clinical outcome
(Table 2). Nevertheless, patients diagnosed as CRs demonstrated a sig-
nificant rise in midtreatment whole-tumor mean ADC value from base-
line values (P < .0001), whereas PRs demonstrated negligible changes
in mean ADC values at 3 weeks after treatment induction.
Parametric Response Mapping of ADC (PRMADC)
Results from PRMADC analysis of the two patients (Figures 1 and 2)
are shown in Figure 3. More than 63% of the tumor volume was found
to have a significant increase in ADC (depicted as red voxels), suggesting
massive cell kill in the tumor mass, for the patient (Figure 1) who ex-
hibited a complete response to therapy (Figure 3A). Regions within the
tumor volume, approximately 9%, were found to have a significant
drop in ADC (depicted as blue voxels). This patient was later found
to have no evidence of malignancy after salvage neck dissection. In
comparison, the patient found to be a PR (salvage neck dissection
was positive for residual cancer) was found to have less of the tumor
volume responding to therapy than the previous patient (Figure 3A),
with 46% of the tumor volume producing a significant increase in
ADC (Figure 3B). A small fraction of the tumor was found to have a
significant decrease in ADC (PRMADC− = 6%).
In Figure 4A, the percentage changes in tumor volume and percent-
age of tumor with significantly increased ADC values as assessed by the
metric PRMADC+ were significantly associated with disease control at
6 months (P < .05). Tumor volume had decreased by up to 43 ± 6%
in CRs, whereas tumors from PRs dropped by only 22 ± 4%. When
the groups were assessed by PRMADC, PRMADC+ was found to be com-
posed of 55 ± 4% of the tumor volume in CRs, with PRs only showing
37 ± 7% of the tumor volume responding to treatment. In contrast,
negligible differences in percentage change in mean ADC (Figure 4A)
and PRMADC− (data not shown) were observed between clinical
groups. Further evaluation of the predictive value of these methods
was performed using an ROC curve analysis correlated with clinical
progression at 6 months (Figure 4B). The percentage changes in tumor
volume and whole-tumor mean ADC were not significantly associated
with clinical progression (area under the curve [AUC] = 0.758, P = .06
and AUC = 0.758, P = .06; respectively), whereas PRMADC+ (AUC =
0.825, P = .02) was predictive of clinical progression at 6 months.
PRMADC− did not provide a significant prognostic measure of response.
Discussion
Recently, we demonstrated in an animal model of HNSCC treated
with chemoradiotherapy that a greater rise in tumor ADC early into
treatment predicted tumor control and animal survival [25], suggest-
ing that the magnitude of early change in tumor ADC values may be
a sensitive early measure of tumor response. As previously reported,
the quantification of changes in diffusion MRI scans during and after
cytotoxic therapies has shown that these changes precede tumor regres-
sion in both animal models and human tumors [18–20,24,26–28].
Therefore, ADC values as assessed by PRM were quantified to deter-
mine whether tumor response could be identified within the first
3 weeks of RT in patients with HNSCC when there would still be time
to adapt treatment based on an early imaging biomarker readout if
it predicted insufficient response to treatment.
In all cases, ADC histogram distributions were heterogeneous and
typically skewed (Figures 1 and 2). These broad ADC distributions are
consistent with the known heterogeneous morphology of malignant
head and neck tumors as previously reported [3, 4, 12]. After 3 weeks
of treatment, the distribution of ADC values generally shifted to a high-
er value, which correlated with a net increase in mean ADC values for
these tumors (Figures 1 and 2). Furthermore, the increase in mean
ADC values was found to be lower in those patients with later progres-
sion of disease than patients without evidence of residual disease (Fig-
ure 4A). The overall heterogeneity of tumor response can attenuate the
prognostic value of the histogram-basedmetric of change inmean tumor
ADC values, which could account for a loss in its sensitivity to differ-
entiate CRs from PRs. Unlike histogram-based whole-tumor ADC
measurements, PRM can circumvent the added complexity of tumor
heterogeneity by accounting for the full anatomic and spatial infor-
mation of the DW-MR images. Regional changes in ADC values within
the tumor were observed in the PRMcolor overlays (Figure 3, A and B).
Table 2. Early Response of Volume and Tumor ADC Values at 3 Weeks after Treatment Initiation.
Volume [cm3] (SEM) ADC [×10−5 mm2/sec] (SEM)
Pretreatment Midtreatment Pretreatment Midtreatment
Primary 28.8 (9.5) 19.3 (7.2) 145.8 (11.3) 163.3 (10.6)
Lymph nodes 43.7 (9.9) 29.6 (10.2) 122.5 (5.0) 153.4 (5.1)
CR 30.6 (5.9) 18.2 (5.4) 133.5 (7.7) 162.9 (6.3)
PR 57.8 (22.3) 47.1 (19.7) 132.7 (8.6) 141.5 (9.5)
Clinical outcome is presented as CR and PR. Bolded values indicate significant differences between
pretreatment and midtreatment values as determined by paired Student’s t test (P < .05). Statistical
differences in tumor volume or ADC were not observed between tumor type and clinical outcome
at pretreatment or midtreatment time points.
Figure 3. Representative slices of PRMADC for patients whose con-
ditions were diagnosed as (A) CR and (B) PR; color-coded VOIs
are overlaid on contrast-enhanced T1-weighted MR images before
therapy and corresponding scatter plots for quantification and dis-
tribution of ADC before and 3 weeks after treatment initiation for
the entire tumor volume. Unity and threshold designating signifi-
cant change in ADC within the scatter plot are presented by red
and black lines, respectively. Voxels with significant increased, de-
creased, or unchanged ADC values were assigned as red, blue, and
green, respectively.
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The volume of tumor with a significant rise in diffusion (PRMADC+;
red voxels) was directly correlated with favorable clinical outcome, which
is similar to that observed in patients with primary brain tumors treated
with RTwhere the PRMADC+ (presented as VI) was directly correlated
with patient survival [19]. In the current study, there was no association
between the volume of tumor with decreasing ADC (PRMADC−; blue
voxels) and clinical progression, which also confirms the results obtained
in brain tumor patients [19]. Thus, in this patient population, we found
that analysis of ADC maps by PRM was more sensitive to small differ-
ences in response than whole-tumor metrics.
Application of PRM in patients with HNSCC requires additional
image after the processing steps not required when applied to brain tumor
patient data. The rapid imaging techniques used for acquiring DWIs,
which uses EPI, suffer from susceptible artifacts at air-tissue interfaces.
This susceptibility results in distortion of the images. Even sequences care-
fully optimized will suffer from some image distortion in the DWI at
moderate b values (≥800 sec/mm2). Fat located in the extracranial head
and neck poses additional difficulties in acquiring DWI data sets. The
signal from fat is especially problematic in DWI. For one, the fat signal
resonates at a slightly different frequency from water, which may result
in a shift in the fat signal from its true anatomic location. To make matters
worse, fat has a very slow diffusivity (0.05 × 10−3 mm2/sec), which, if near
the tumor, may cause an underestimation of the true ADC. Finally, mo-
tion artifacts, which are very common in patients with advanced-stage
head and neck cancer often with salivary stasis and difficulty breathing,
introduce difficulties in aligning images acquired even during the same
scanning session. All of these imaging artifacts pose hardships when apply-
ing image fusion. Unlike rigid-body registration, which is used on serial
image data sets from glioma patients, nonlinear image fusion algorithms
are required to register DWIs to anatomic or serial DWI data sets.
The limitations of the current study include the relatively small
number of patients and the single time point evaluated to measure
changes in diffusion. Of 15 patients, only 3 were found to have progres-
sive disease 6 months after treatment. To offset these small numbers,
multiple tumors in a patient were treated independently resulting
in 26 individual samples. This approach was deemed to be valid as re-
sponse outcomes were assessed individually by tumor pathology for
each tumor and not for the patient as a whole. Optimization of PRM
sensitivity for the quantification of early treatment response in patients
with HNSCC may be improved by using a different time interval. In
fact, preclinical models have shown that the greatest ability for diffu-
sion MRI to predict response was before a significant change in tumor
volume had occurred [17,24,29]. Therefore, given the significant tumor
regression observed after 2 to 3 weeks of treatment, the maximal PRM
responsemay have occurred earlier than themeasurement interval evalu-
ated in this present study. A similar phenomenon was observed in
patients treated with neoadjuvant chemoradiotherapy for rectal cancer
where DWI at 1 week identified a group of patients with a rise in ADC
who later had favorable pathologic features (necrosis and negative sur-
gical margins), whereas diffusion assessment at 1 month demonstrated
an overall decline in diffusion, which was not prognostic and which the
authors attributed to fibrosis [30,31]. In addition, investigators at the
University of Pennsylvania recently obtained encouraging results with
diffusion MRI as early as 1 week into a course of chemoradiotherapy
for head and neck cancer with minimal volume changes [14]. As a note,
all of these studies used the percentage change in mean ADC as their
outcome metric. Here, we observed no predictive value in mean
ADC, whereas PRMADC had produced significant results between path-
ologically distinct groups. Because of the differences observed between
the recent report of Kim et al. [14] and the present results, further in-
vestigation of the efficacy of mean ADC and PRMADC with a larger
cohort of patients and studied over multiple time points is warranted.
This would provide for an opportunity to optimize the timing of the
DW-MRI interval examination, thus potentially improving the sensi-
tivity of the PRM imaging biomarker metric.
A significant result of this present study was the determination that it
was feasible to perform high-order registration (warping) on DWI head
and neck lesions using interval examinations. Imaging of the head and
neck with EPI can be problematic because of image distortion resulting
from susceptibility at air-tissue interfaces [4]. Even while acquiring data
using parallel imaging technique, such as SENSE, image distortion
can render full-affine registration algorithms ineffective for fusing serial
images. We found that higher-order registration techniques were re-
quired for the implementation of PRM. Because inaccurate registration
of serial maps would randomize the PRM metrics resulting in a lack
of correlation with clinical outcomes, the fact that PRM analysis was
determined to statistically correlate to the clinical progression supports
the accuracy of the registration technique used in this study.
Figure 4. Box plot (A) and receiver operating characteristic curve (B) of response metrics: percentage change in tumor volume (red) and
mean ADC values (blue) and PRM analysis representing the percentage of the tumor volume, which exhibited a significant increase in
ADC (red; PRMADC+). *Significant differences between outcome groups as assessed by an unpaired Student’s t test with P < .05.
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In summary, to date, NSOPT is the standard of care for patients
whose conditions were diagnosed with HNSCC, resulting in the pres-
ervation of functionality (e.g., swallowing and speech) in the patient
while maintaining the current survival rate. Diffusion MRI provides
voxel-wise information on tumor status after chemoradiotherapy.
Tumor lesions in serial MR images were registered into a single geo-
metric frame using a deformable image registration algorithm. This
was a key step for implementing the PRM, which is a voxel-wise tech-
nique for quantifying therapeutic-induced changes. Diffusion measure-
ments as assessed by PRMADC, and not percentage change of the mean
diffusion, at 3 weeks into a course of chemoradiotherapy were found to
be predictive of disease control at 6 months in patients. The change in
the ADC, as measured byDW-MRI and assessed by PRM,may serve as
a potential imaging biomarker for quantifying early therapeutic efficacy
in patients with HNSCC that can be readily incorporated into a clinical
head and neck cancer treatment protocol. DW-MRI, when assessed
by PRM, has the potential to provide prognostic and spatial informa-
tion during NSOPTof head and neck cancer. In this study, significant
treatment-induced increases in tumor ADC values were detectable and
spatially resolved using PRM analysis. The results of this study provide
the foundation and rationale for pursuing a larger trial to determine
more fully the potential of PRM analysis for DW-MRI data as an early
biomarker for monitoring therapeutic efficacy in patients with head and
neck cancer. On validation in a larger study, PRM may aid in the indi-
vidualization of head and neck cancer treatment regimens.
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